Shingles

August 22nd 2025

The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.

July 17th 2025

The FDA approves a prefilled syringe for the zoster vaccine recombinant, enhancing shingles vaccination convenience and effectiveness for adults 50 years and older.

July 4th 2025

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.

May 9th 2025

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.